Navigation Links
Whistleblower's extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
Date:10/25/2012

BALTIMORE, Oct. 25, 2012 /PRNewswire/ --  The healthcare fraud case that Boehringer Ingelheim Pharmaceuticals Inc. settled today with the government for $95 million was due in large measure to a former Boehringer Ingelheim sales representative-turned-whistleblower who made extraordinary efforts to stop Boehringer Ingelheim's pharma marketing practices that allegedly defrauded Medicare and other government healthcare programs and promoted uses of its drugs that endangered patients' health.

The whistleblower, Robert Heiden, filed a "qui tam" (whistleblower) lawsuit in 2005 with detailed allegations about Boehringer Ingelheim's kickback programs and "off-label" marketing of certain drugs for unapproved uses. He provided extensive assistance to the government's investigation. For instance, he:

  • Wore a wire and recorded conversations at the government's request.
  • Analyzed 1.5 million pages of documents and more than 2 million "call notes" pharma reps kept after each visit with a doctor or doctor's office..
  • Prepared background notebooks to assist the government with interviews of at least 15 witnesses.
  • Arranged for an undercover FBI agent to attend a marketing lecture sponsored by Boehringer Ingelheim where the speaker discussed and encouraged uses of the drug Micardis that hadn't been approved and weren't supported by research.

"Rob Heiden was an exceptionally committed whistleblower who led the charge to stop the marketing of prescription drugs for uses that hadn't been approved and could endanger patients' health," said Colette G. Matzzie, a Washington, DC, attorney with Phillips & Cohen LLP, which represents Heiden. "Even the FBI was impressed with his help, particularly that he was able to get an undercover FBI agent into a Boehringer Ingelheim marketing seminar after Rob had already left the company."

Under the False Claims Act, whistleblowers whose cases result in recoveries for the government are entitled to a reward of 15 percent to 25 percent of the recovery. For the work Heiden and his attorneys did on the case, the government is awarding Heiden over 21 percent.

The allegations involved the off-label marketing of four drugs: Aggrenox, Atrovent, Combivent and Micardis. Pharma companies are prohibited from marketing drugs for uses the U.S. Food and Drug Administration (FDA) hasn't approved, although doctors may prescribe drugs for off-label uses.

The more egregious off-label marketing charges in the whistleblower lawsuit against Boehringer Ingelheim include:

  • Promoting the use of Aggrenox as one of the best drugs to reduce the risk of heart attacks and other cardiovascular risks despite the lack of evidence to support those claims. Aggrenox had been approved by the FDA only for prevention of secondary stroke.
  • Promoting the use of Atrovent and Combivent by children to treat asthma and coughs associated with a cold or flu, when the drugs had not been tested on kids, and promoting the use of excessively high, unapproved doses of Atrovent and Combivent in patients where only lower dosages were approved and considered safe.
  • Marketing Micardis for prevention of "metabolic syndrome" (medical conditions, such as insulin resistance, that increase the risk for heart disease and stroke) and prevention of early kidney disease when the FDA had approved Micardis only for treatment of hypertension.

"I was concerned that doctors were basing their treatment decisions on false information," Heiden said. "Promoting off-label treatments with potential serious consequences just to increase sales is heinous behavior."

"Boehringer Ingelheim's alleged off-label marketing practices helped it grow from a small company to one of the largest, privately held companies in the world," said Peter Chatfield, a Washington, DC, attorney with Phillips & Cohen. "Many doctors chose Boehringer Ingelheim's products over less-expensive, equally effective drugs as a result of the company's marketing practices."

Heiden worked as a sales representative for Boehringer Ingelheim for 14 years in Florida. Phillips & Cohen filed his qui tam lawsuit in federal district court in Baltimore "under seal" as required by the False Claims Act. The government investigated the allegations and joined the case, which was unsealed after the settlement was reached.

"Assistant U.S. Attorneys Roann Nichols and Tom Corcoran, former Assistant United States Attorney Jamie Bennett, trial attorney Brian McCabe with the Department of Justice Civil Division and the state team from the National Association of Medicaid Fraud Control Units, in particular, did a tremendous job for the government," said Matzzie.

Invaluable support was provided in the investigation by the FBI, the Office of Inspector General at the Department of Health and Human Services (HHS-OIG), the FDA, the Department of Defense's Tricare program, the Office of Personnel Management and the U.S. Department of Veterans Affairs.

About Phillips & Cohen LLP
Phillips & Cohen is the nation's most successful law firm representing whistleblowers. Its cases have resulted in governments recovering more than $8.5 billion in civil settlements and criminal fines. http://www.phillipsandcohen.com. Twitter @Fraudmatters.

 

 

 


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKlines (GSK) $3 Billion Whistleblower Settlement Has Paid for One Of Americas Most Expensive Failed Corporate Internal Investigations, Qui Tam Whistleblowers Attorneys Say
2. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
3. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
4. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
5. Sequenom Announces Exercise In Full Of Over-Allotment Option And Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
6. ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
7. Neuralstem to Raise $7.0 Million in Registered Direct Offering
8. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
9. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
10. Henry Schein Announces New $500 Million Credit Facility
11. Philips ermöglicht noch besseren Zugang zu Behandlungen für häufige Todesursache in den USA durch Bereitstellung seines einmillionsten AED
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... 26, 2016 , ... American orthopedic surgeon and internationally recognized ... Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference and Expo ... in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem cell therapy ...
(Date:5/26/2016)... TN (PRWEB) , ... May 26, 2016 , ... ... fitness education and products recently hosted the first PowerWave Instructor Certification Course in ... who lead a group of fitness professional through the 8 hour interactive course ...
(Date:5/26/2016)... ... 2016 , ... On May 23rd during the National Eye Institute’s “Healthy Vision ... advocate, was honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon ... banks of the Nile to fill their red clay pots with life-sustaining water.” Said ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite Ergonomics ... leadership and to further develop their rapidly expanding portfolio of customer and end ... a concentration in Marketing and an M.B.A. with concentration in management from Bryant ...
Breaking Medicine News(10 mins):